A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-10-18
Adverse events
Grade 2 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 51); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-26 (study day 171); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-04 (study day 210); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-04-04 (study day 515); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-05-20 (study day 561); relationship: N
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-10-08 (study day 702); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2025-01-08 (study day 794); relationship: Y
Data queries
No data queries.